Biocon Biologics launches biosimilar to treat Crohn’s disease in United States
- Posted on February 24, 2025
- By Financial Express
- 9 Views
Biocon Biologics launches biosimilar to treat Crohn’s disease in United States
YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.
